ChagasTranslation

 

 

  • Target disease: Chagas
  • Main Partners (since project start): AbbVie, USA; Bioaster, France; Centre for Drug Candidate Optimisation (CDCO), Monash University, Australia; Epichem, Australia; Eurofins CEREP, France; Griffith Institute for Drug Discovery, Griffith University, Australia; London School of Hygiene and Tropical Medicine, UK; WuXi App Tech, China.
  • Project start: 2017
  • Funding (since project start): Department for International Development (DFID), UK; Dutch Ministry of Foreign Affairs (DGIS), The Netherlands; Federal Ministry of Education and Research (BMBF through KfW), Germany; Médecins Sans Frontières/Doctors without Borders, International; Swiss Agency for Development and Cooperation (SDC), Switzerland.

 

Overall objective:

  • Optimize leads issued from the hit-to-lead 205 series, and identify pre-clinical candidates with the potential to fulfill the target product profile for Chagas disease

 

 

This series is part of the GSK/DDU/DNDi discovery collaboration portfolio, following a research agreement made in early 2018. Work on the series has concentrated on safety profiling and exploratory toxicology for the selected front-runners. Decision on if and how to proceed will be made once the complete BENDITA trial data are available. 

Following curative activity in vivo observed for several lead compounds of the 205 series, work in 2017 concentrated on better understanding the necessary parameters for obtaining cure in animals, in particular by testing different regimens and doses while exploring further optimization. Further characterization of this series is ongoing, and compounds are being profiled for candidate nomination. More than 400 compounds have been synthesized by this programme to date.


Last update: February 2019